{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-001611","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.811791+00:00","generated_at":"2026-06-19T21:49:51.971421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viking Q4 net loss $0.26/shr; cash $155M; NASH study data expected Q2 2023","bullets":["Net loss $19.6M ($0.26/shr) for Q4 2022 vs $12.4M ($0.16/shr) in Q4 2021; R&D expense rose to $16.2M.","Full-year 2022 net loss $68.9M ($0.90/shr) vs $55.0M ($0.71/shr) in 2021; cash $155M (down from $202M).","Enrollment completed for Phase 2b VOYAGE study of VK2809 in NASH/fibrosis; topline data expected Q2 2023.","Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; initial data expected Q1 2023.","Phase 1b study of VK0214 in X-ALD enrolling; data expected H2 2023; cash runway beyond key milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-001611","json":"https://secwatch.observer/filing/0001564590-23-001611.json","markdown":"https://secwatch.observer/filing/0001564590-23-001611.md","text":"https://secwatch.observer/filing/0001564590-23-001611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000156459023001611/0001564590-23-001611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000156459023001611/vktx-8k_20230208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:49:51.971421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d66ca26073e819885bb3b365e2c7b13cbc27e33f","claim":"Viking Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On February 8, 2023, we issued a press release reporting our financial results for the fourth quarter and year ended December 31, 2022 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607678/000156459023001611/0001564590-23-001611-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}